Prevalence of metabolic syndrome in patients with schizophrenia

Middle East Current Psychiatry

Volumn 18, Issue 2, 2011, Pages 109-117

  Roshdy, Reda ^a  

^a AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Diabetes; Metabolic syndrome; Obesity; Schizophrenia

Indexed keywords

EID: 84859774730     PISSN: 20905408     EISSN: 20905416     Source Type: Journal    
DOI: 10.1097/01.XME.0000395562.63321.35     Document Type: Article

References (34)

1. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007; 7:14.
2. Ohaeri JU, Akanji AO. Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord 2010; 9:91-98.
3. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
4. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (Suppl 7):22-31. (Pubitemid 32402182)
5. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999; 187:496-502. (Pubitemid 29422604)
6. Lyketsos CG, Dunn G, Kaminsky MJ, Breakey WR. Medical comorbidity in psychiatric inpatients relation to clinical outcomes and hospital length of stay. Psychosomatics 2002; 43:24-30. (Pubitemid 34214158)
7. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66:51-57. (Pubitemid 38030344)
8. Hanley AJG, Karter AJ,Williams K, Festa A, D'Agostino RB Jr,Wagenknecht LE, et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005; 112:3713-3721. (Pubitemid 43739511)
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716. (Pubitemid 35403784)
10. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabet Care 2001; 24:683-689. (Pubitemid 32893993)
11. Cleeman JI. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497. (Pubitemid 32433843)
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752. (Pubitemid 41532612)
13. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Available: http://www.idf.org/webdata/docs/ metabolic-syndrome-definition.pdf.
14. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004; 49:753-760. (Pubitemid 40094948)
15. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80:19-32. (Pubitemid 41587460)
16. De Hert MA, Van Winkel R, Van Eyck D, Hanssens L,Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83:87-93.
17. Hatata H, Abd Elsalam M, Algohary G, Okda S. Risk of metabolic syndrome among Egyptian patients with schizophrenia. Endocr Abstr 2010; 21:P105.
18. Cerit C,Özten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turkish J Psychiatry 2008; 19: 124-132.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23:469-480.
20. Badr HE, Al Orifan FH, Amasha MMF, Khadadah KE, Younis HH. Prevalence of metabolic syndrome among healthy kuwaiti adults: primary health care centers based study. Middle East J Family Med 2007-2008; 5:8-11.
21. Rezaei O, Khodaie Ardakani MR, Mandegar MH, Dogmehchi E, Goodarzynejad H. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int J Psychiatry Med 2009; 39: 451-462.
22. El Tayebani M. Metabolic syndrome in chronic inpatients with schizophrenia compared to their first episode illness. Bull Alex Fac Med 2007; 43:517-529.
23. Basu R, Brar JS, Chengappa KN, John V, Parepally H, Gershon S, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004; 6:314-318. (Pubitemid 39077092)
24. Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006; 12:5-10. (Pubitemid 44378042)
25. Hägg S, Lindblom Y, Mjo ̈rndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006; 21:93-98. (Pubitemid 43740316)
26. Heiskanen T, Niskanen L, Lyytikä inen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579. (Pubitemid 36618288)
27. Tillmann HL, Chen DF, Trautwein C, Kliem V, Grundey A, Berning Haag A, et al. Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 2001; 48:714-718. (Pubitemid 32378596)
28. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jä rvelin MR, Laurén LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort Study. J Clin Psychiatry 2005; 66: 559-563.
29. Littrell K, Perry R, Hilligoss N. Insulin resistance and syndrome X among schizophrenic patients. Insulin resistance and syndrome X among schizophrenic patients. American psychiatric association 156th annual meeting; May 17-22. San Francisco, California: American Psychiatric Association; 2003.
30. Kurt E, Altnbas K, Alatas G, Özver I?. Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Türkiye'de Psikiyatri 2007; 9:141-145.
31. Moreno TSA, González RT, Fleta JLH, Pérez PL. Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr 2007; 35:359-367.
32. Yazici MK, Yaǧcoǧlu AE, Ertuǧrul A. The prevalence of metabolic syndrome in schizophrenic patients: a preliminary report. Eur Neuropsychopharmacol 2005; 15:520-521.
33. Kato MM, Beatriz Currier M, Gomez CM, Hall L, Gonzalez Blanco M. Prevalence of metabolic syndrome in hispanic and non-hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004; 6:74-77.
34. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005; 27:1930-1941. (Pubitemid 43293215)